SB Relinquishes Frovatriptan Royalties As Final Step In Antitrust Review
Executive Summary
SmithKline Beecham will receive up to $25 mil. in payments from Vernalis in exchange for surrendering its 7% royalty on the pending antimigraine agent Miguard (frovatriptan).
You may also be interested in...
Elan Frova Migraine Launch To Follow Finalized Co-Marketing Agreement
Elan's Frova acute migraine therapy launch awaits finalization of a co-marketing agreement, which is expected to take place by year-end
Elan Frova Migraine Launch To Follow Finalized Co-Marketing Agreement
Elan's Frova acute migraine therapy launch awaits finalization of a co-marketing agreement, which is expected to take place by year-end
Elan Seeks Frovelan Partner, More Sales Reps For Migraine Product Launch
Elan expects to launch the migraine therapy Frovelan this year with a co-promotion partner, VP-Investor Relations John Howarth indicated March 27 at the Banc of America Securities Healthcare Conference in Las Vegas.